Filings · News reference

Veraxa Biotech Files Prospectus Related To The Resale Of Up To 25M Ordinary Shares By The Selling Shareholder

Jul 31, 2026, 9:17 PMBenzinga Newsdesk

-SEC FIling

Read original source More filings news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Jul 31, 2026, 9:17 PM
Checked: Jul 31, 2026, 9:17 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 24, 2026, 11:10 AMBenzinga Newsdesk
VERAXA Biotech Announces Initial Results From Strategic Research Collaboration To Develop Next-Generation Antibody Oligonucleotide Conjugates For Autoimmune And Chronic Immune Diseases; In Early In Vitro Studies, An AOC Candidate Demonstrated Greater Potency
Read original at benzinga
VRXA
BenzingaJul 27, 2026, 2:56 PMBenzinga Newsdesk
Veraxa Biotech shares are trading higher after the company announced the advancement of the bispecific ADC program VXA-222.
Read original at benzinga
VRXA
BenzingaJul 27, 2026, 11:07 AMBenzinga Newsdesk
VERAXA Biotech Advances Bispecific ADC VXA‑222 With OmniAb Milestone, Moving Alliance Into Next Phase Of Cancer Therapy Discovery
VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA" or the ", Company", ))), an emerging leader in designing novel cancer therapies, today announced the advancement of bispecific ADC (bsADC) program VXA-222,
Read original at benzinga
OABI VRXA